Anthony D. Kelleher

1 month ago | gut.bmj.com | Robert O'Neill |Logan Gardner |Anthony D. Kelleher |Roger Pamphlett

Cookies and privacyWe and our 138 partners store and access personal data, like browsing data or unique identifiers, on your device. Selecting "I Accept" enables tracking technologies to support the purposes shown under "we and our partners process data to provide," whereas selecting "Reject All" or withdrawing your consent will disable them. If trackers are disabled, some content and ads you see may not be as relevant to you.

Dec 1, 2024 | nature.com | Gail B. Cross |Intan P Sari |Han Nguyen |Christina C. Chang |Anthony D. Kelleher |Jim O’Doherty

AbstractAdjunctive rosuvastatin for rifampicin-susceptible pulmonary tuberculosis (rs-PTB) shows no effect on microbiological or radiological outcomes in a phase IIb randomised, controlled trial (NCT04504851). We explore the impact of adjunctive rosuvastatin on 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) imaging in a sub-study of 24 participants.

Mar 19, 2024 | unsw.edu.au | Anthony D. Kelleher

Immune abnormalities have largely resolved at 24 months in a cohort of patients with long COVID, providing optimism that long COVID can resolve over time. Biomarkers for long COVID that were present in patients at eight months have largely resolved by 24 months among a cohort of people who contracted COVID-19 during Australia’s first wave.